Abstract
A public-private partnership to establish biomarkers of dementia in Down's syndrome could aid the development of preventive therapies for the dementia associated with both Down's syndrome and Alzheimer's disease, based on the apparent common pathogenic role of amyloid precursor protein in the two conditions.
MeSH terms
-
Alzheimer Disease / etiology
-
Alzheimer Disease / genetics
-
Alzheimer Disease / prevention & control*
-
Amyloid beta-Peptides / adverse effects
-
Amyloid beta-Peptides / genetics
-
Apolipoprotein E4 / adverse effects
-
Apolipoprotein E4 / genetics
-
Down Syndrome / etiology
-
Down Syndrome / genetics
-
Down Syndrome / prevention & control*
-
Genetic Markers / genetics
-
Genotype
-
Humans
-
Secondary Prevention* / methods
Substances
-
Amyloid beta-Peptides
-
Apolipoprotein E4
-
Genetic Markers